Membranous nephropathy
Conditions
Interventions
CsA group:oral CsA and glucosteroid
RTX group:intravenous RTX
CTX:Intravenous cyclophosphamide and glucosteroid
Sponsors
Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years, male or female; 2. Membranous nephropathy proved by renal pathology; 3. Eliminate secondary membranous nephropathy (HBV, HCV, malignant tumor, SLE, autoimmune disease or drug associated MN); 4. EPI-GFR >= 30ml/min; 5. Sign informed consent; 6. 24h proteinuria >= 4g/d and serum albumia < 30g/L despite 3 months treatment with maximum tolerated doses of ACEI and/or ARB.
Exclusion criteria
Exclusion criteria: 1. Patients already used RTX; 2. Allergic to investigational drug; 3. Recent operation plan; 4. Severe acute or chronic infection (sepsis, respiratory/urinary/digestive infection), or patients receiving antibiotic treatment; 5. Severe cardiac lesion, NYHA III-IV; 6. Presist WBC 2 times of normal range);or HBV-DNA positive; 10. Newly diagnosed malignant tumor or patients receiving radiotherapy/chemotherapy; 11. Sever edema; 12. Condition unstable to receive the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete or Partial remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| relapse;eGFR;death;thrombosis/embolism complication; | — |
Countries
China
Contacts
Public ContactChen Nan
Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
Outcome results
None listed